Related Experiment Videos

Defining CD95 as a tumor suppressor gene

M Müschen1, U Warskulat, M W Beckmann

  • 1Institute of Genetics, Department of Immunology and Medizinische Klinik I, Universität zu Köln, Cologne, Germany. markus.mueschen@uni-koeln.de

Journal of Molecular Medicine (Berlin, Germany)
|September 23, 2000
PubMed

Insights

The CD95 (Apo-1/Fas) receptor system regulates apoptosis and lymphocyte balance. Mutations in the CD95 gene increase tumor risk, suggesting CD95 acts as a tumor suppressor, while CD95L expression promotes cancer progression.

Area of Science:

  • Immunology
  • Molecular Biology
  • Oncology

Background:

  • The CD95 (Apo-1/Fas) receptor-ligand system is crucial for apoptosis and lymphocyte homeostasis.
  • Tumor cells often exhibit reduced susceptibility to CD95-mediated apoptosis.
  • Mutations in the CD95 gene are linked to increased risk of lymphoid and solid tumors.

Purpose of the Study:

  • To discuss the role of CD95 as a tumor suppressor gene.
  • To explore the implications of CD95 ligand (CD95L) expression in malignant progression.
  • To analyze the significance of CD95 and CD95L expression in tumor development.

Main Methods:

  • Literature review and conceptual discussion.
  • Analysis of evidence linking CD95 mutations to cancer risk.
  • Examination of studies on CD95L expression in various tumor types.

Main Results:

  • CD95 mutations are associated with high risks of lymphoid and solid tumors.
  • Malignant cells often express CD95L aberrantly, inducing apoptosis in bystander cells.
  • Neoplastic CD95L expression contributes to local tissue destruction, invasion, and metastasis.

Conclusions:

  • CD95 functions as a tumor suppressor gene.
  • Aberrant CD95L expression by tumors promotes malignant progression and immune evasion.
  • Dysregulation of the CD95 system (loss of CD95, gain of CD95L) is significant for tumor progression.

Related Concept Videos